19. Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139:189—201.
20. van de Veen W, Wirz OF, Globinska A, Akdis M. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. Curr Opin Immunol. 2017;48:74—81.
21. Stanic B, van de Veen W, Wirz OF et al. IL-10-overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol. 2015;135:771—780.
22. Boonpiyathad T, Meyer N, Moniuszko M et al. High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers. Allergy. 2017;72:407—415.
23. Patil SU, Ogunniyi AO, Calatroni A et al. Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. J Allergy Clin Immunol. 2015;136:125—134.
24. Shamji MH, Kappen JH, Akdis M et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017;72:1156—1173.
25. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T (H) 2 and tolerogenic responses. Nat Immunol. 2010;11 (8):647—655.
26. Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol. 2014;5:7.
27. Sun W, Wei JW, Li H, Wei FQ, Li J, Wen WP. Adoptive cell therapy of tolerogenic dendritic cells as inducer of regulatory T cells in allergic rhinitis. International forum of allergy & rhinology. 2018;8 (11):1291—1299.
28. Tanaka Y, Nagashima H, Bando K et al. Oral CD103 (-) CD11b (+) classical dendritic cells present sublingual antigen and induce Foxp3 (+) regulatory T cells in draining lymph nodes. Mucosal Immunol. 2017;10:79—90.
29. Deniz G, Akdis M, Aktas E, Blaser K, Akdis CA. Human NK1 and NK2 subsets determined by purification of IFN-gammasecreting and IFN-gamma-nonsecretingNK cells. Eur J Immunol. 2002;32 (3):879—884.
30. Deniz G, Erten G, Kucuksezer UC, et al. Regulatory NK cells suppress antigenspecific T cell responses. J Immunol. 2008;180 (2):850—857.
31. Ferstl R, Frei R, Barcik W, et al. Histamine receptor 2 modifies iNKT cell activity within the inflamed lung. Allergy. 2017;72 (12):1925—1935.
32. Globinska A, Kowalski ML. Innate lymphoid cells: the role in respiratory infections and lung tissue damage. Exp Rev Clin Immunol. 2017;13 991—999.
33. Kortekaas Krohn I, Shikhagaie MM, Golebski K, et al. Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy. 2018;73 (4):837—850.
34. Lao-Araya M, Steveling E, Scadding GW, Durham SR, Shamji MH. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol. 2014;134 (5):1193—1195.
35. Fan DC, Wang XD, Wang CS, Wang Y, Cao FF, Zhang L. Suppression of immunotherapy on group 2 innate lymphoid cells in allergic rhinitis. Chin Med J (Engl). 2016;129:2824—2828.
36. Morita H, Kubo T, Ruckert B, et al. Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. J Allergy Clin Immunol. 2019;143:2190—2201.
37. Wang S, Xia P, Chen Y, et al. Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell. 2017;171 (1):201—216.
38. Scadding GW, Calderon MA, Shamji MH et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: The GRASS randomized clinical trial. JAMA. 2017;317:615—625.
39. Freiberger SN, Zehnder M, Gafvelin G, Gronlund H, Kundig TM, Johansen P. IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy. 2016; 71: 1366—1370.
40. Orengo JM, Radin AR, Kamat V et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018;9:1421.
41. Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Mechanisms of Aeroallergen Immunotherapy: Subcutaneous Immunotherapy and Sublingual Immunotherapy. Immunology and allergy clinics of North America. 2016;36 (1):71—86.
42. Mondoulet L, Dioszeghy V, Busato F et al. Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut-sensitized mice. Allergy. 2019;74 (1):152—164.
43. Pawlowski M, Jerzynska J, Podlecka D, Stelmach W, Majak P, Stelmach I. Effectiveness of immunotherapy in children depends on place of living – A pilot study. Allergol Immunopathol (Madr). 2017;45 (3):272—275.
44. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121:1467—1472.
45. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288—1296.
46. Slovick A, Douiri A, Muir R, Guerra A, Tsioulos K, Hay E et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol. 2017;139:1830—1839.
47. Mantyla J, Thomander T, Hakulinen A et al. The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults. Immun Inflamm Dis. 2018;6:307—311.
48. Begin P, Nadeau KC. Changes in peanut-specific T-cell clonotype with oral immunotherapy. J Allergy Clin Immunol. 2015;135:1636—1638.
49. Tanaka Y, Nagashima H, Bando K et al. Oral CD103 (-) CD11b (+) classical dendritic cells present sublingual antigen and induce Foxp3 (+) regulatory T cells in draining lymph nodes. Mucosal Immunol. 2017;10:79—90.
50. Smaldini PL, Trejo F, Cohen JL, Piaggio E, Docena GH. Systemic IL-2/anti-IL-2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells. Allergy. 2018;73:885—895.
51. Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2017;72:435—443.
52. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137:339—349.
53. Patterson AM, Bonny AE, ShielsWE, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016;116:168—170.
54. Johansen P, von Moos S, Mohanan D, Kundig TM, Senti G. New routes for allergen immunotherapy. Hum Vaccin Immunother. 2012;8:1525—1533.
55. Lee SP, Choi SJ, Joe E et al. A pilot study of intralymphatic immunotherapy for house dust mite, cat, and dog allergies. Allergy Asthma Immunol Res. 2017;9:272—277.
56. Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016;17:10. doi:10.1186/s12931-016-0324-9
57. Aricigil M, Muluk NB, Sakarya EU et al. New routes of allergen immunotherapy. Am J Rhinol Allergy. 2016;30:193—197.
58. Campana R, Moritz K, Neubauer A et al. Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients. Sci Rep. 2017;7 (1):11657.
59. Jones